

OP-3-07

PCE
IHW
S

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RE APPLICATION OF:

Mochly-Rosen & Chen

APPLICATION No.: 10/007,761

FILED: November 9, 2001

FOR: PEPTIDES FOR ACTIVATION AND
INHIBITION OF δ PKC

EXAMINER: Snedden

ART UNIT: 1653

CONF. No: 3055

Request for Continued Examination (RCE) Transmittal

Mail Stop RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

This is a Request for Continued Examination (RCE) under 37 C.F.R. §1.114 of the above-identified application.

1. Submission required under 37 C.F.R. §1.114☐ Previously submitted:☐ Consider the Amendment under 37 C.F.R. §1.116 previously filed on ____.☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on ____.☒ Enclosed:☒ Amendment☒ Supplemental Information Disclosure Statement, Form PTO-1449, and 1 Reference2. Miscellaneous☐ Suspension of action on the above-identified application is requested under 37 C.F.R. §1.103(c) for a period of ____ months.

3. Fees

- ☒ A check in the amount of \$375.00 is enclosed to cover the following fees.
 - ☒ RCE fee required under 37 C.F.R. §1.17(e)
- ☒ The Director is hereby authorized to charge any underpayment in fees (or credit any overpayments) to Deposit Account No. 50-2207.


Respectfully submitted,

Date: 9/1/04

Judy M. Mohr
Judy M. Mohr
Registration No. 38,563

Correspondence Address:

Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Mochly-Rosen & Chen

APPLICATION No.: 10/007,761

FILED: November 9, 2001

FOR: **PEPTIDES FOR ACTIVATION AND
INHIBITION OF δ PKC**

EXAMINER: Snedden

ART UNIT: 1653

CONF. No: 3055

Amendment Under 37 C.F.R. § 1.111

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This amendment is submitted concurrently with a Request for Continued Examination and is a submission responsive to the Final Office action dated June 2, 2004.

Amendments to the claims are reflected in the listing of claims beginning on page 2.